Vertebral Spine News
-
New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ADT in combination ...
By Bayer AG
-
RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology
RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is ...
By RevBio Inc.
-
NBC News’ TODAY Features the Minimally Invasive Intracept® Procedure for Chronic Vertebrogenic Low Back Pain
Relievant Medsystems shared today that the company’s breakthrough chronic low back pain treatment, the Intracept Procedure, was featured on NBC’s TODAY this morning. The full segment can be viewed here. “This is an exciting story, not only for the patients I’ve treated, but also for the millions of patients with chronic vertebrogenic low back pain who will now learn about ...
-
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months. Salt Lake City, UT – February 25, 2022 – ...
-
Nanox Announces Issuance of American Medical Association New Category III CPT® Code for Its Coronary Artery Calcium Population Health Solution
NEVE ILAN, Israel--(BUSINESS WIRE)--Jan. 11, 2022-- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and its deep-learning medical imaging analytics subsidiary, Nanox.AI, today announced that the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT) code for quantitative CT tissue ...
-
Fonar Board of Directors Appoints Independent Director
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company´s board of directors and audit committee. Timothy Damadian, president and CEO of FONAR, said, “Our primary source of income and growth is attributable to FONAR’s ...
-
Fonar Announces First Fiscal Quarter Earnings
Total MRI scan volume at the HMCA-managed sites increased 11.6 % to 48,469 scans for the quarter ending September 30, 2021 versus the same quarter one year earlier. This is highest quarterly total in the Company’s history. Diluted Net Income per Common Share increased 53% to $0.55 for the quarter ended September 30, 2021 versus the same quarter one year earlier. Total Revenues-Net ...
-
Relievant Medsystems Announces New Vertebrogenic Low Back Pain ICD-10 Diagnosis Code
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the Centers for Disease Control and Prevention (CDC) has designated an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code specifically for vertebrogenic low back pain. The new diagnosis code – M54.51 ...
-
Gelmetix closes successful £5 million capital raise, progresses to first-in-human trial
Medtech start-up Gelmetix, the developer of a first-in-class polymer treatment for chronic lower back pain, has closed a successful £5 million Series C equity financing round. Following successful in-vivo and pre-clinical studies, the University of Manchester spin-out will now use the additional capital to fund its upcoming first-in-human (FIH) trial and preparing for the pivotal study. ...
-
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of ...
-
FONAR Subsidiary, HMCA, Expands with Acquisition in Yonkers, New York
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning, announced today that it has acquired a Stand-Up MRI facility in Yonkers, New York, from where its diagnostic imaging management subsidiary, Health Management Company of America (HMCA) will provide non-medical management services for Comprehensive MRI of New York, P.C. Tim Damadian, president and CEO of FONAR Corporation, said, ...
-
FONAR To Ring The Nasdaq Stock Market Closing Bell, As It Celebrates 50th Birthday of MRI
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, will ring the Nasdaq Stock Market Closing Bell on March 9, 2021. Nasdaq and FONAR selected this day as it is 50 years since the discovery of MRI by Raymond V. Damadian, M.D., FONAR’s founder and chairman, was published in the widely-read, peer-reviewed scientific journal Science on March 19, 1971.* To access the live ...
-
Nanox and USARAD Introduce Radiology AI Second Opinion Program
NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces an extension of its strategic collaboration with USARAD Holdings Inc., a US Joint Commission accredited teleradiology and telemedicine company, to launch an advanced radiology diagnostics service combining over 300 expert radiologists and ...
-
FDA Clears First Nanotechnology Peek Devices for Spinal Intervertebral Fusion
NASHUA, N.H.–(BUSINESS WIRE)–Vallum Corporation, a medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market a polyetheretherketone (PEEK) spinal interbody fusion device with a PEEKplus® nanotextured1 surface created by Vallum’s proprietary and patented Accelerated Neutral Atom Beam (ANAB) technology. ...
-
Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure
Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the completion of a $70 million equity financing. The round was led by new investor Vensana Capital alongside Lightstone Ventures with participation from existing investors Endeavour Vision, New Enterprise Associates, Morgenthaler Ventures and Canaan Partners. ...
-
Wenzel Spine Announces Acquisition of Statera Spine
Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders, today announced that it has completed the acquisition of Statera Spine, a pre-operative diagnostics and quantitative data software solution that improves treatment decisions for spine patients. Statera Spine is a software enabled spine imaging analytics ...
-
FONAR Set to Join Russell 3000 and 2000 Indexes
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning, reported today that upon the opening of U.S. markets on June 29, 2020, FONAR will, as part of the annual reconstitution of the Russell Indexes, be joining the broad-market Russell 3000 Index and the Russell 2000 Index. The Russell 3000 Index is a market-capitalization-weighted equity index that tracks the performance of the 3,000 ...
-
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Phase 1/2 first-in-human U.S. clinical study of IDCT, an allogeneic, injectable Discogenic Cell therapy for degenerative disc ...
-
Japanese Clinical Study of DiscGenics` Cell Therapy for Disc Degeneration Passes Initial Safety Review
Salt Lake City, UT and Tokyo, Japan – January 7, 2020 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has passed the initial planned safety review of its double-blinded clinical study evaluating ...
-
DiscGenics Announces Publication of Preclinical Data for Disc Degeneration Treatment in The Spine Journal
Salt Lake City, UT – September 24, 2019 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the online publication of a study in The Spine Journal [1] that summarizes the results of preclinical ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you